Biotech Values

[Biowatch]

GILD up 10% on Atripla sales for HIV

Tamiflu royalties helped too, but given that Tamiflu has a ten year shelf life I assume sales will drop now that most countries have stocked up in advance of bird flu concerns.

>HIV powers growth

Fourth-quarter product sales rose 56% year-over-year, to $768.1 million, with sales of its HIV treatments soaring 67% to $642.4 million. Royalty, contract and other revenue came in 13% above last year, at $131.1 million, with $113.2 million in Tamiflu royalties from F. Hoffmann-La Roche Ltd.

Sales of the first once-a-day treatment for HIV treatment Atripla, which Gilead jointly developed with Bristol-Myers Squibb Co., rose to $137.4 million from $68.4 million in the third quarter. The FDA approved Atripla, which contains Bristol-Myers' Sustiva and Gilead's Truvada, which itself consists of the company's drugs Viread and Emtriva, for sale last summer. Gilead expects Atripla will be approved for sale in the European Union sometime in the second half of the year, Chief Executive John Martin said on the conference call.<
http://www.marketwatch.com/news/story/gilead-shares-rally-fresh-high/story.aspx?guid=%7B9468A29F%2D2...